Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.
• The Russell US indexes are reconstituted annually, capturing the 4,000 largest publicly traded US companies as of April 30.
• FTSE Russell determines index membership based on objective market capitalization rankings and style attributes.
• This process ensures that the Russell indexes accurately reflect the evolving structure of the US equity market.
“This milestone reflects the significant growth and development Tonix has experienced over the past year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We look forward to the increased visibility and awareness that inclusion in the Russell Indexes brings as we advance toward the potential FDA approval and planned launch of TNX-102 SL for the management of fibromyalgia later this year.”
• Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
• According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.
• For more information on the Russell 3000® Index and Russell 2000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
• Tonix is a fully-integrated biotech company focused on transforming therapies for pain management and vaccines for public health challenges.
• Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization.
• The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD).
• Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.
• Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years.
• TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments.
• Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
• Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
• This press release and further information about Tonix can be found at www.tonixpharma.com.
• This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995.
• Forward-looking terms include: “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “intend,” and similar expressions.
• These statements are based on Tonix's current expectations, but actual results may differ materially due to various risks.
• Key risk factors include (but are not limited to):
• Tonix does not undertake to update any forward-looking statements after the date of publication.
• Investors are advised to review the risk factors detailed in Tonix’s Form 10-K (Dec 31, 2024) and subsequent SEC filings.